Drug · CHEMBL181
DIAZOXIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DIAZOXIDE. Drugs and targets, record CHEMBL181. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL181
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Diazoxido, Diazoxidum, Eudemine injection, Hypertonalum, NSC-64198, NSC-76130, SCH 6783, SCH-6783, SRG 95213, SRG-95213
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 15 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| KCNJ11 | ATP-sensitive inward rectifier potassium channel 11 | Potassium channel, inwardly rectifying, subfamily J, member 11 opener | OPENER | https://conductscience.org/library/genes/3767 |
| KCNJ8 | ATP-sensitive inward rectifier potassium channel 8 | Potassium channel, inwardly rectifying, subfamily J, member 8 opener | OPENER | https://conductscience.org/library/genes/3764 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials22
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03566511 | Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide | Phase 2 | 37 | 2025-05-31 | diazoxide | Its name | ClinicalTrials.gov |
| NCT00683774 | Insulin and Polycystic Ovary Syndrome | 21 | 2014-08-21 | diazoxide | Its name | ClinicalTrials.gov | |
| NCT01028846 | Central Mechanisms That Regulate Glucose Metabolism in Humans | Phase 4 | 10 | 2025-03-14 | diazoxide | Its name | ClinicalTrials.gov |
| NCT02049385 | Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression? | Phase 1/2 | 10 | 2017-10-13 | diazoxide | Its name | ClinicalTrials.gov |
| NCT03608163 | Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) | Phase 4 | 4 | 2025-09-11 | diazoxide | Its name | ClinicalTrials.gov |
| NCT00994149 | Diazoxide In the Management Of Hypoglycemic Neonates | Phase 2/3 | 100 | diazoxide | Its name | ClinicalTrials.gov | |
| NCT03540758 | Regulation of Endogenous Glucose Production by Central KATP Channels | Phase 2 | 100 | diazoxide | Its name | ClinicalTrials.gov | |
| NCT00631033 | DZX Mediated Insulin Suppression in Obese Men | Phase 2 | 51 | diazoxide | Its name | ClinicalTrials.gov | |
| NCT00131755 | Efficacy of Diazoxide in Type 1 Diabetes | Phase 4 | 40 | diazoxide | Its name | ClinicalTrials.gov | |
| NCT00306683 | Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions | Phase 3 | 40 | diazoxide | Its name | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Diazoxide vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT01028846 | Trial comparisons |
| Diazoxide vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT01028846 | Trial comparisons |
| PCOS Subjects vs Normal Subjects: serious adverse events | 0 of 8 | 0 of 9 | 17 | NCT00683774 | Trial comparisons |
| Diazoxide vs Matched Placebo: deaths from any cause | 0 of 7 | 0 of 7 | 14 | NCT03566511 | Trial comparisons |
| Diazoxide vs Matched Placebo: serious adverse events | 0 of 7 | 0 of 7 | 14 | NCT03566511 | Trial comparisons |
| Diazoxide vs Placebo: deaths from any cause | 0 of 6 | 0 of 3 | 9 | NCT02049385 | Trial comparisons |
| Diazoxide vs Placebo: serious adverse events | 0 of 6 | 0 of 3 | 9 | NCT02049385 | Trial comparisons |
| Naloxone vs Placebo (for Naloxone): deaths from any cause | 0 of 3 | 0 of 4 | 7 | NCT03608163 | Trial comparisons |
| Naloxone vs Placebo (for Naloxone): serious adverse events | 0 of 3 | 0 of 4 | 7 | NCT03608163 | Trial comparisons |
Papers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Trail Making Test B | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL181
GET https://conductscience.org/api/drugs/v1/CHEMBL181/trials?page=2